Influence of oral melatonin on natural and gonadotropin-induced ovarian function in the domestic cat

Behavioral and cardiovascular effects of a single dose of gabapentin or melatonin in cats: a randomized, double-blind, placebo-controlled trial

OBJECTIVES

The aim of this study was to verify whether a single oral dose of gabapentin (100 mg) or melatonin (3 mg) given 60 mins before a cardiac evaluation would reduce anxiety without interfering with heart rate (HR), systemic blood pressure (SBP), electrocardiogram (ECG) and echocardiographic indexes.

METHODS

Seventy-five client-owned healthy cats underwent two sets of cardiac assessments 60 mins apart, randomly divided into gabapentin, melatonin and placebo groups. The interval between treatment and the second ECG and SBP measurement was 60 mins, and 70 mins for echocardiography. A compliance score (CS) classified the behavior, focusing on the ease of handling.

RESULTS

Most variables did not change between the examinations. The placebo group showed more significant changes (SBP, tricuspid annular plane systolic excursion, HR during echocardiography, aortic flow velocity, S' wave from lateral mitral annulus), but they were not considered to be hemodynamically relevant. Gabapentin and melatonin significantly increased the cats' compliance without interfering with cardiac assessment. Eight cats presented with mild sedation, seven after gabapentin and one after melatonin. No major side effects were observed.

CONCLUSIONS AND RELEVANCE

Gabapentin tranquilized the cats when it was given 60 mins prior to ECG and SBP measurement, and 70 mins prior to echocardiography, without interfering with systolic echocardiographic indexes. Melatonin also decreased the CS, but without sedation in most cases. The waiting period may have relaxed the cats in the placebo group, resulting in lower SBP measurements. However, this tranquility did not last as some echocardiographic changes signaled a sympathetic predominance.

Reversible Control of Reproduction In Queens: Mastering the use of reproductive drugs to manipulate cyclicity

BACKGROUND

The literature is full of papers reporting side effects of progestogens in cats; however, they are, in fact, safe drugs, as discussed in this article. Gonadotropin-releasing hormone (GnRH) agonists and melatonin are additionally a practical solution for controlling cyclicity in queens, but they also have some contraindications and need to be used carefully.

CLINICAL RELEVANCE

Mastering the use of reproductive drugs allows feline practitioners to handle many more clinical situations than can be solved using surgery. It is not necessary to be a specialist in reproduction to be able to halt cyclicity in a valuable breeding queen using hormones.

EQUIPMENT AND TECHNICAL SKILLS

A sound knowledge of appropriate dosages and criteria for patient selection for all reproductive drugs currently used in feline reproduction is the best guarantee of owner satisfaction and of ensuring the queen's health. Availability of a serum progesterone assay, either in-house or via an external laboratory, is also important, in order to confirm a queen is at an appropriate stage of the reproductive cycle for treatment.

AUDIENCE

This article is aimed principally (but not exclusively) at veterinarians working with cat breeders and whose clientele is increasingly interested in alternative methods of controlling reproduction in pet queens. Surgery is no longer the only choice, and practitioners who manage to keep abreast of new developments will be able to address clients' needs in a modern, professional way.

EVIDENCE BASE

This review draws on a vast body of scientific evidence-based literature. Previously, personal (and sometimes misinformed) opinions, such as the proposed dangerous side effects of progestogens, have been perpetuated in the scientific literature. The papers cited in this review have therefore been carefully scrutinised to distinguish reliable information based on controlled studies from non-evidence-based information.

Preoperative calming effect of melatonin and its influence on propofol dose for anesthesia induction in healthy dogs

OBJECTIVE

To investigate the preoperative calming effect of melatonin and its influence on propofol dose for anesthesia induction in dogs.

STUDY DESIGN

Prospective, randomized, blinded, placebo-controlled clinical study.

ANIMALS

A total of 50 healthy, adult, client-owned dogs scheduled for elective surgery.

METHODS

Dogs were equally divided into treatment group M, which received 5 mg kg^-1 melatonin, and placebo-control group P (sucrose), both administered orally 2 hours prior to induction of anesthesia. Dogs were subjectively characterized and further designated as skeptical (group S; n = 18) or trustful (group T; n = 32). Behavior, calming effect and vital parameters (pulse rate, respiratory rate, blood pressure, rectal temperature) were evaluated before and after treatment. Propofol dose [mg kg^-1 intravenously (IV)] to allow endotracheal intubation and anesthesia induction quality was documented. Data were analyzed using a general linear model and Mann-Whitney U tests.

RESULTS

Dogs in group MS (n = 10) were calmer than those in group PS (n = 8) at 90 minutes after drug administration (p = 0.047). Group MT (n = 15) required less propofol (5.98 ± 0.96 mg kg^-1) than group PT (n = 17; 7.04 ± 1.82 mg kg^-1 IV; p = 0.048) and group MS (9.48 ± 3.22 mg kg^-1 IV; p = 0.007). Group PS required 7.69 ± 2.71 mg kg^-1 IV. Skeptical dogs showed more reactions during induction (p = 0.013). Vital parameters were within physiological ranges before and after treatment.

CONCLUSION AND CLINICAL RELEVANCE

Results showed that melatonin may be used to reduce propofol dose for anesthesia induction in trustful dogs. Skeptical dogs benefitted from the calming properties. Potentially, melatonin could be used to minimize the level of excitement before general anesthesia and to reduce the required propofol dose for induction.

Effects of Melatonin on Early Pregnancy in Mouse: Involving the Regulation of StAR, Cyp11a1, and Ihh Expression

To test whether melatonin plays an important role in the process of early pregnancy, melatonin was given in drinking water to pregnant mice at different gestation stages. These included mice who were given melatonin 14 days prior to their successful mating (confirmed by vaginal plug) (Group A), after successful mating (Group B), and 14 days prior to and until after successful mating (Group C). Melatonin administration significantly enhanced serum as well as ovarian melatonin levels in the mice. It was observed that melatonin did not affect the natural estrous of mice. On day 0.5 of gestation (D0.5), melatonin not only elevated progesterone (P) secretion, but also upregulated expressions of StAR and Cyp11a1, the two marker genes of corpus luteum in ovaries (p < 0.05). Group A had a significantly lower estradiol (E₂) secretion and a higher number of implantation sites as well as litter size than controls (p < 0.05) and also had an increased Ihh expression in endometrium of D7.5 gestation. Melatonin treatment after successful mating improved the progesterone (P) secretion at D7.5 of gestation (p < 0.05) and significantly induced leukaemia inhibitory factor (LIF) expression (p < 0.05). Our study indicates that melatonin treatment up-regulated the genes involved in pregnenolone synthesis in ovary and Ihh expression in uterine endometrium. The mechanisms of melatonin to improve embryo implantation related to their actions on promoting the development of corpus luteum before gestation and helping to specify uterine receptivity in early pregnant mice.

Effect of melatonin on the reproductive cycle in female cats: a review of clinical experiences and previous studies

Practical relevance Cat breeders aim to suppress the sexual cycle for a defined period. This is a challenge as most preparations available for this intention are orally administered progestins; however, these drugs may have side effects, especially when used over a long period of time. Long-acting gonadotropin-releasing hormone agonist implants have been used successfully to suppress the oestrous cycle in cats for a longer period. After removal of the implant, the duration of action was shortened; however, the re-occurrence of normal cyclicity cannot be foreseen. The search for alternatives is therefore ongoing. Clinical challenges Another possibility for oestrus control is orally administered melatonin preparations; however, previous studies have shown that the effect was not satisfactory. After subcutaneous application of a melatonin implant developed for induction of oestrus in sheep (Melovine; Ceva Santé Animale), duration of oestrus suppression was shown to differ highly in individuals and in some cases no effect was observed. Nevertheless, it is used for short-term oestrus suppression in female cats. Aims This article provides an overview of recent studies and clinical experiences of the use of melatonin as a contraceptive in cats. It explains the function of melatonin in cats, discusses previous studies, provides clinical experience with Melovine (27 cases) and elucidates advantages and disadvantages. Evidence base Information provided in this article is drawn from the published literature and the author's own clinical experience.

Alternative methods for feline fertility control: Use of melatonin to suppress reproduction

PRACTICAL RELEVANCE

Reversible contraceptives are highly desired by purebred cat breeders for managing estrous cycles and by scientists managing assisted reproduction programs. A variety of alternative medicine approaches have been explored as methods to control feline fertility.

SCOPE

In the field of veterinary homeopathy, wild carrot seed and papaya have been used for centuries. Both appear to be safe, but their efficacy as feline contraceptives remains anecdotal. In contrast, the use of melatonin in cats has been investigated in a number of studies, findings from which are reviewed in this article.

RATIONALE

Cats are seasonally polyestrous (they cycle several times during their breeding season) and are described as long-day breeders because endogenous melatonin negatively regulates estrous cyclicity. Exogenous melatonin administered parenterally also suppresses ovarian activity in cats, and long-term oral or subcutaneous melatonin administration is safe.

CHALLENGES

The therapeutic use of melatonin is limited by its short biological half-life (15-20 mins), its poor oral bioavailability and its central effects in reducing wakefulness. Research is required to determine whether higher doses, longer-release formulations, repeated administration or combination implants might overcome these limitations.

Efeito da iluminação constante sobre a placenta de ratas: um estudo morfológico, morfométrico e histoquímico

A presente pesquisa analisou o efeito da iluminação constante sobre a estrutura placentária de ratas, abordando parâmetros morfológicos, morfométricos e histoquímicos. Vinte ratas albinas foram submetidas aos seguintes tratamentos: 12hL/12hE por 60 dias, e acasaladas em seguida (GI); ausência de luz por 60 dias, e acasaladas em seguida (GII); iluminação constante por 60 dias, e acasaladas em seguida (GIII); iluminação constante por 60 dias, acasaladas em seguida e tratadas com melatonina (GIV). O estímulo luminoso foi em torno de 400 lux. A melatonina foi administrada na água (400mg/mL de etanol). Os resultados mostraram que histologicamente o GII apresentou vacuolização das células do trofospongio. Morfometricamente, o GIII apresentou camada do labirinto com redução no número de trofoblastos sinciciais e maior vascularização materno-fetal, hiperplasia e hipertrofia das células trofoblásticas gigantes, uma maior média da área total do disco placentário; porém, na camada de trofospongio, as células trofoblásticas e trofoblastos sinciciais não diferiram nos grupos experimentais. As placentas do GIV foram semelhantes às do GI. Histoquimicamente não houve alterações nas fibras colágenas, elásticas, reticulares e glicosaminoglicanas ácidas. Em conclusão, a iluminação constante promove alterações morfológicas e morfométricas na placenta de ratas, podendo acarretar redução funcional e restrições ao crescimento fetal. Essas alterações são abolidas pela reposição de melatonina.

Effect of combined lignan phytoestrogen and melatonin treatment on secretion of steroid hormones by adrenal carcinoma cells

OBJECTIVE

To investigate the in vitro effect of the combination of lignan enterolactone (ENL) or lignan enterodiol (END) with melatonin on steroid hormone secretion and cellular aromatase content in human adrenal carcinoma cells.

SAMPLE

Human adrenocortical carcinoma cells.

PROCEDURES

Melatonin plus ENL or END was added to cell culture medium along with cAMP (100μM); control cells received cAMP alone. Medium and cell lysates were collected after 24 and 48 hours of cultivation. Samples of medium were analyzed for progesterone, 17-hydroxyprogesterone, androstenedione, aldosterone, estradiol, and cortisol concentration by use of radioimmunoassays. Cell lysates were used for western blot analysis of aromatase content.

RESULTS

The addition of ENL or END with melatonin to cAMP-stimulated cells (treated cells) resulted in significant decreases in estradiol, androstenedione, and cortisol concentrations at 24 and 48 hours, compared with concentrations in cells stimulated with cAMP alone (cAMP control cells). The addition of these compounds to cAMP-stimulated cells also resulted in higher progesterone and 17-hydroxyprogesterone concentrations than in cAMP control cells; aldosterone concentration was not affected by treatments. Compared with the content in cAMP control cells, aromatase content in treated cells was significantly lower.

CONCLUSIONS AND CLINICAL RELEVANCE

The combination of lignan and melatonin affected steroid hormone secretion by acting directly on adrenal tumor cells. Results supported the concept that this combination may yield similar effects on steroid hormone secretion by the adrenal glands in dogs with typical and atypical hyperadrenocorticism.

Reproduction control in cats: new developments in non-surgical methods

PRACTICAL RELEVANCE

Reproduction control is an area of feline medicine that is assuming increasing importance in companion animal practice. Signs of oestrus such as increased vocalisation, rolling on the ground and a very short interoestrous interval may negatively influence the relationship between cat and owner, and prompt the owner to seek a method of reproduction control. In breeding catteries, control of reproduction may be needed as part of a planned breeding programme.

CLINICAL CHALLENGES

Surgical contraception is not always the owner's wish - especially when a cat may be intended for future breeding. Besides, ethical principles and animal welfare legislation in an increasing number of countries are imposing restrictions on this 'classical approach' to reproduction control. Progestins are routinely used as non-surgical alternatives in cases where fertility is to be preserved, but the associated risks of uterine disease, mammary tumours, fibroadenomatosis or diabetes mellitus have to be taken into account - especially in predisposed animals. Modern, effective pharmacological alternatives are available for managing oestrous suppression and unwanted pregnancy. Detailed knowledge of the physiology of the oestrous cycle in the cat is necessary to ensure that the appropriate treatment is chosen for the individual animal and its owner.

AUDIENCE

This article presents an update for small animal practitioners on these alternative methods; specifically, the use of slow-release GnRH agonists or melatonin implants for hormonal contraception, and the antiprogestin aglepristone for pregnancy termination.

EVIDENCE BASE

Several studies have documented the mode of action and risk of side effects of the traditional alternative to surgical castration - treatment with progestins. Evidence underpinning the safety and efficacy of GnRH agonists and melatonin implants for suppression of fertility in queens and toms is reviewed.

Suppression of estrus in cats with melatonin implants

The objective of this study was to assess the efficacy of a subcutaneous melatonin implant to suppress estrus in queens (felis catus). The hypothesis was that this implant would temporarily and reversibly suppress estrus in queens without producing any clinically detectable side effects. Fourteen adult queens were maintained in cages under artificial illumination (14h light:10h dark) for 45 d and then randomly assigned to one of two treatments. At interestrus, queens received a single subcutaneous melatonin implant (18mg; Melovine [CEVA Sante Animal, Libourne, France]; MEL: n=9), or a single subcutaneous placebo implant without melatonin (0mg; PLA; n=5). At the next estrus, all queens received a second MEL (n=9) or PLA (n=5) implant. Blood samples were taken when queens displayed estrous signs and during interestrus to measure estradiol (E(2)) and progesterone (P(4)), respectively, by radioimmunoassay. There were no significant differences in duration of the interestrus interval in PLA cats, regardless of whether the implants were placed during interestrus or estrus (6.0+/-9.7 d vs. 6.0+/-9.7 d, respectively; least square means [LSM]+/-SEM). However, when MEL implants were placed during interestrus, the duration of interestrus was approximately twice as long as that occurring when MEL implants were placed during estrus (113.3+/-6.1 d vs. 61.1+/-6.8 d, respectively; P<0.01). Serum E(2) and P(4) concentrations were similar in queens with PLA and MEL implants and in queens that received implants in estrus and interestrus. In conclusion, a subcutaneous MEL implant effectively and reversibly suppressed estrus in queens for approximately 2 to 4 mo with no clinically detectable side effects.

Application of assisted reproduction for population management in felids: The potential and reality for conservation of small cats

Assisted reproductive technology (ART), using the primary applied tools of AI, ET, and sperm and embryo cryopreservation, has been promoted over the past decades for its potential to conserve endangered wildlife, including felids. However, if the goal is efficient, consistent production of viable offspring for population management, then the 'potential' of ART has yet to become 'reality' for any non-domestic cat species. For the five small-sized felids (i.e., Brazilian ocelot, fishing cat, Pallas' cat, Arabian sand cat, black-footed cat) managed by Species Survival Plans (SSPs) in North American zoos, achieving this potential may be an absolute necessity if genetically viable captive populations are to be maintained into the next century. Modeling programs suggest that current SSP populations are not sustainable without periodic introduction of new founders and improved demographic parameters, including longer generation intervals and larger population sizes. ART provides the means to address each of these management challenges. In each small cat SSP species, fecal hormone metabolite assays and seminal analysis have proven useful for characterizing basal reproductive parameters, a necessary prerequisite to developing ART. Of the five SSP species, ART has been used to produce living offspring only in the ocelot, including after AI with frozen-thawed spermatozoa and following transfer of frozen-thawed IVF embryos. The true efficacy of these techniques, however, is still unknown. To improve the applicability of ART for population management, priorities for immediate research include further investigation of ovarian stimulation protocols, sperm and embryo cryopreservation methods, embryo culture systems, and fetal and neonatal viability following ART.

Natural and gonadotropin-induced ovarian activity in tigers (Panthera tigris) assessed by fecal steroid analyses

Fecal samples were collected from female tigers (n = 17) to compare endocrine patterns associated with natural ovarian activity with those after chorionic gonadotropin ovulation induction and artificial insemination (AI). Baseline fecal estradiol concentrations were 65.77 +/- 3.61 ng/g with estrual peaks of 167.39 +/- 9.92 ng/g and an anovulatory cycle length of 17.96 +/- 0.70 days. Peak fecal estradiol was higher when females were housed with a male for breeding (262.30 +/- 41.43 vs. 165.30 +/- 3.67 ng/g; P < 0.05). The majority of animals showed some seasonal differences in fecal estradiol however, patterns were inconsistent. Fecal progestagens increased only after breeding confirming tigers are primarily induced ovulators. The non-pregnant luteal phase was 34.50 +/- 1.85 days in duration. In pregnant tigers, fecal progestagens remained elevated for 108 days until parturition and the diagnosis of pregnancy was possible based on the elevated fecal progestagens after 35 days of gestation. Tigers were administered equine chorionic gonadotropin (eCG) to stimulate follicular growth and human chorionic gonadotropin (hCG) to induce ovulation prior to AI [200 IU eCG/100 IU hCG (n = 5); 400 IU eCG/200 IU hCG (n = 2); 500 IU eCG/100 IU hCG (n = 2); 1000 IU eCG/750 IU hCG (n = 11); 1000 IU eCG/1000 IU hCG (n = 4)]. None of the tigers subjected to AI became pregnant (n = 9). Fecal endocrine patterns in gonadotropin-stimulated tigers were considerably different from those observed in naturally bred tigers. In particular, fecal estradiol concentrations were higher than those observed during natural estrus and remained elevated for longer periods of time in tigers administered the higher doses of gonadotropins typically used in conjunction with AI in this species. These abnormal endocrine patterns may help explain the poor success rate of AI in this species.

Ovarian control for assisted reproduction in the domestic cat and wild felids

Of the 37 felid species, all but the domestic cat are classified as threatened with extinction in all or part of their native range. Additionally, the domestic cat is a valuable model for human biomedical research. Propagating some wild felids as well as domestic cat populations serving as human models is a major challenge primarily due to difficulties in transporting animals between facilities to ensure the pairing of genetically matched individuals, behavioral incompatibility between pairs and low fertility. Artificial insemination (AI) and in vitro fertilization/embryo transfer (IVF/ET) are powerful tools for helping manage rare populations. Developing successful assisted reproductive techniques requires knowledge of the female reproductive cycle and precise control of ovarian activity. Successful ovarian stimulation for AI and IVF/ET has been achieved in at least one-third of all cat species. However, sensitivity to a given gonadotropin treatment appears highly species-specific, and poor responses are common, particularly in felid species that exhibit spontaneous ovulations. Furthermore, current gonadotropin regimens have been demonstrated to perturb female reproductive function often leading to reduced fertility. Overall, ovarian response to exogenous hormonal stimulation has been highly variable, and pregnancy success after AI or IVF/ET remains low (<20%) in most species. Therefore, there is an immediate need to develop improved regimens that would allow more predictable ovarian responses in felids. We contend that recent research involving the use of progestins to control the ovary prior to gonadotropin stimulation shows promise for providing consistent ovarian stimulation in felids.

Comparative endocrinology of domestic and nondomestic felids

The ability to track gonadal and adrenal activity via hormones is key to optimizing health and reproduction. Through decades of study, a great deal has been learned about the biology of female domestic cats, including endocrine function. More recently, comparative endocrine studies have greatly expanded our knowledge base of nondomestic felids as well. The latter has been possible largely through the development of noninvasive fecal steroid metabolite analysis techniques, which currently is the method of choice for monitoring endocrine function in wildlife species, including felids. It now is well-recognized that a range in endocrine patterns exists among Felidae, with many traits and mechanisms being uncommon, if not unique. There is a high degree of variability in the type of ovulation (spontaneous versus induced) expressed across the taxon. Even within species, some individuals exhibit ovulation that is only induced, whereas others ovulate spontaneously as well. Steroid metabolism also differs in that metabolites are excreted almost exclusively in feces, with very little steroid found in urine. Across species there are marked differences in seasonal and social influences on reproduction, adrenal responses to husbandry practices, and ovarian responses to assisted reproductive procedures. This means that developing strategies to improve health and reproduction of felids must be done on a species by species basis. This paper summarizes current knowledge on the reproductive endocrinology of female domestic and nondomestic cats, and describes how the rapidly growing endocrine database is aiding ex situ management efforts.

Expression of melatoninergic receptors in human placental choriocarcinoma cell lines

BACKGROUND

Melatonin crosses the placenta and enters the fetal circulation. Moreover, experimental data suggest a possible influence of melatonin on placental function and fetal development in humans. To date, the expression and role of melatonin receptors in human placenta choriocarcinoma cell lines and in human term placental tissues remain to be elucidated.

METHODS AND RESULTS

Results from RT-PCR, western blotting and confocal microscopy demonstrated that the MT1, MT2 and RORalpha1 melatonin receptors are expressed in the human term placental tissues and in choriocarcinoma cell lines JEG-3 and BeWo. Furthermore, enzyme-linked immunosorbent assay showed that 6-chloromelatonin (a melatonin agonist) inhibits, in a dose-dependent manner, forskolin-stimulated hCG-beta secretion in JEG-3 (P < 0.001) and BeWo (P < 0.05) cells but had no effect on basal human chorionic gonadotrophin (hCG-beta) levels. This effect of 6-chloromelatonin on forskolin-stimulated HCG-beta secretion was abolished by pertussis toxin (PTX), suggesting that melatonin regulates hCG-beta production by an action involving an inhibitory Gi/o protein. In PTX-treated BeWo cells, 6-chloromelatonin stimulated basal hCG-beta secretion (P < 0.001).

CONCLUSION

These results demonstrate, for the first time, the expression of melatonin receptors in human term placental tissues and in choriocarcinoma cells and suggest a possible paracrine/autocrine function for melatonin in human placenta.

Ovarian follicular development and oocyte quality in anestrous ewes treated with melatonin, a controlled internal drug release (CIDR) device and follicle stimulating hormone

The objective of the current study was to determine the effects of hormonal treatments on ovarian follicular development and oocyte quality in anestrous ewes. Multiparous crossbred (RambouilletxTarghee) ewes were given melatonin implants (MEL) and/or controlled internal drug release (CIDR) devices in conjunction with follicle stimulating hormone (FSH) during anestrus (March-May). In Experiment 1, ewes (n=25) were assigned randomly to four groups (n=4-7/group) in a 2x2 factorial arrangement [+/-MEL and +/-CIDR], resulting in Control (no treatment), CIDR, MEL, and MEL/CIDR groups, respectively. Ewes received an implant containing 18 mg of melatonin (Melovine) on Day 42 and/or a CIDR from Days 7 to 2 (Day 0: oocyte collection). In Experiment 2, ewes (n=12) were assigned randomly to two groups (n=6/group; 1CIDR or 2CIDR) and received the same type of melatonin implant on Day 60. All ewes received a CIDR device from Days -22 to -17 and 2CIDR ewes received an additional CIDR device from Days -10 to -2. In both experiments, ewes were given FSH im twice daily (morning and evening) on Days -2 and -1 (Day -2: 5 units/injection; Day -1: 4 units/injection). On the morning of Day 0, ovaries were removed, follicles>or=1 mm were counted, and oocytes were collected. Thereafter oocytes were matured and fertilized in vitro. In Experiment 1, the number of visible follicles and the rates of oocyte recovery and in vitro maturation were similar (P>0.10) for Control, CIDR, MEL and MEL/CIDR (overall 29.7+/-2.9%, 89.9+/-7.1% and 95.0+/-2.0%, respectively). The rates of in vitro fertilization (IVF) were lower (P<0.01) for CIDR and MEL/CIDR than for Control and MEL groups (10.3% and 10.1% versus 20.0% and 18.5%, respectively). In Experiment 2, the number of visible follicles, and the rates of oocyte recovery and in vitro maturation were similar (P>0.10) for 1CIDR and 2CIDR groups (overall 27.3+/-3.2%, 92.1+/-2.7% and 90.2+/-1.9%, respectively). However, the rates of IVF were lower (P<0.01) for 2CIDR than 1CIDR group (30.2% versus 58.0%, respectively). In summary, when treatment with P4 commenced only 2 d before oocyte collection, rates of IVF were reduced in both experiments. Therefore, progestin treatment protocols used in ovine IVF programs should be carefully designed to minimize adverse effects on fertilization rates. In addition, melatonin treatment did not affect follicular development and oocyte quality for anestrous ewes.